MedTrace Logo

(3D) Ultrasound Imaging Liver and Kidney

NCT03844399 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2025-07-20

No results posted yet for this study

Summary

This study is to assess the addition of 3D ultrasound guidance during standard care ablation or biopsies of liver or kidney tumours. 3D ultrasound only differs from conventional 2D ultrasound in that the ultrasound transducer is mounted on a special assembly that moves the transducer in precise, stepped movements while a succession of 2D images are collected by the computer. Special software written specifically for 3D ultrasound precisely aligns these 2D images into a 3-demensional volume , allowing area in question to be viewed in many different planes. 3D ultrasound is a safe, fast, non-invasive imaging procedure. Ultrasound images will be checked against the pre- and post- procedure CT images to make sure the tumours were completely removed or properly targeted during biopsy.

Conditions

Interventions

DEVICE

Ablation

The medical device will passively record image data during the standard care ablation

DEVICE

Biopsy

The medical device will passively record image data during the standard care biopsy

Sponsors & Collaborators

  • Western University, Canada

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-03
Primary Completion
2026-07-31
Completion
2027-02-28

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03844399 on ClinicalTrials.gov